Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 338

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide

Open access
Schade, Sebastian, Mollenhauer, Brit, Trenkwalder, Claudia·2020·Movement Disorders Clinical Practice

Abstract

There has been a steadily growing armamentarium of drugs for the symptomatic treatment of Parkinson's disease (PD). Consequently, as various various pharmaceutical agents are used, it has become more difficult to perform and compare clinical trials with different medication regimens. Given that levodopa remains the gold standard treatment, conversion factors have been proposed to calculate l-dopa equivalent doses (LEDs) for each drug to facilitate comparison of medication regimens. Adding up LEDs of each drug leads to a daily total LED that is artificial but feasible and—if used as a standard scheme—comparable internationally. Since the last widely accepted proposal of LEDs for PD drugs by Tomlinson et al.,1 there has been no update. We hereby propose LED conversion factors for opicapone and safinamide, which are currently missing, but urgently needed, in ongoing clinical trials and observational studies. Opicapone is a new peripheral catechol-O-methyl transferase (COMT) inhibitor. Tomlinson et al. have proposed a conversion ratio, rather than a conversion factor, for inhibitors of COMT activity, by considering the mode of action of these drugs in terms of prolongation of the duration of the coadministered l-dopa treatment. The suggested ratio for entacapone is 0.33 × LD (coadministered l-dopa dose); the suggested ratio for tolcapone is LD × 0.5, respectively.1 For opicapone, we suggest a ratio higher than for entacapone, given that our literature search (see Supporting Information S1) and clinical experience suggest that opicapone is slightly more efficacious than entacapone.2 However, there are no intriguing data suggesting that opicapone might be more efficient than tolcapone3; we therefore propose using the same ratio for calculating the LED of opicapone as is used for tolcapone (LD × 0.5). Safinamide is mainly a reversible monoamine oxidase-B (MAO-B) inhibitor. Other proposed mechanisms likely play no relevant additional role concerning l-dopa equivalence. For safinamide, we propose an LED of 100 mg, independently of the actual administered dose, given that full reversible inhibition of MAO-B activity is already reached in the lowest commercially available preparations of safinamide.4 In the previous scheme,1 this would make safinamide equivalent to 1 mg of rasagiline and 10 mg of oral selegiline. All existing LED proposals (including our current additions) are based on clinical experience and empirical approaches. They pooled together studies by individual researchers, which provided sparse and inconsistent data. Consequently, these proposals are neither objective nor inherently scientific. To the best of our knowledge, there has not been a thorough evaluation so far. There needs to be a critical retrospective discussion on whether calculating LED reflects what we ought to measure and whether conclusions drawn from these calculations are valid. This pseudo-validity remains the major limitation of calculating LEDs. In conclusion, we believe that our proposed conversions fit reasonably well into the previous scheme of conversion factors (Table 1) and still sufficiently reflect the potential of both drugs. However, they follow the same limitations as the previous proposals.1 Prospectively, the LED conversion factor scheme needs a global reassessment with an attempt to use more objective measurements (using validated rating scales, adjusting for placebo, etc.) and thereby allowing the inclusion of new agents. We thank Anne-Marie Williams for language editing and formatting the manuscript. We thank Joaquim Ferreira for his valuable input and for reviewing an earlier version of the manuscript (including detailed results and conclusions of our literature search). (1) Research Project: A. Conception, B. Organization, C. Execution; (2) Manuscript: A. Writing of the First Draft, B. Review and Critique. S.S.: 1A, 1B, 1C, 2A, 2B B.M.: 1C, 2B C.T.: 1A, 2B Ethical Compliance Statement: The authors confirm that the approval of an institutional review board or patient consent was not required for this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflicts of Interest: The authors report no sources of funding and no conflicts of interest. Financial Disclosures for previous 12 months: S.S. has received salaries from the EU Horizon 2020 research and innovation program under grant agreement No. 634821 and from the Deutsche Forschungsgemeinschaft (DFG) under grant agreement No. MO 2088/5-1. B.M. has received honoraria for consultancy from Roche, Biogen, UCB, and Sun Pharma Advanced Research Company. B.M. is a member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson's Research and has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mdc3.12921

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 338

Metadata

Authors
Schade, S., Mollenhauer, B., & Trenkwalder, C.
Venue
Movement Disorders Clinical Practice
Publisher
Wiley
Published
2020-03-16
Volume
7
Issue
3
Pages
343-345
ISSN
2330-1619 (ISSN-L)
OpenAlex
W3007197464
Cited by
338
References
4
FWCI
14.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.